secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0000950170-25-080568
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics unveils updated corporate presentation with clinical progress
--------------------------------------------------------------------------------

- Updated presentation highlights [212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors with sustained anti-tumor activity and tolerability.
- Melanoma program [212Pb]VMT01 Phase 1/2a trial for metastatic melanoma includes TEAE safety data and trial design.
- PSV359 Phase 1/2a trial targets FAP-α expression on tumor and stroma for multiple cancers.
- Company describes pre-targeting platform and on-demand supply chain for regional radiopharmaceutical delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025080568/0000950170-25-080568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025080568/catx-20250603.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-080568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer